<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35731316</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Missense mutation in ATXN2 gene (c.2860C&#x2009;&gt;&#x2009;T) in an amyotrophic lateral sclerosis patient with aggressive disease phenotype.</ArticleTitle><Pagination><StartPage>6087</StartPage><EndPage>6090</EndPage><MedlinePgn>6087-6090</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06229-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">ALS symptoms have been previously described only in the context of ATXN2 CAG expansions, whereas missense mutations of the gene have never been described in ALS patients.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We identified a novel missense mutation (c.2860C&#x2009;&gt;&#x2009;T) of ATXN2, for which in silico analysis showed a possible pathogenic effect on protein expression, in a patient presenting an aggressive disease phenotype.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our findings&#xa0;raise the possibility for unknown genetic factors interacting with ATXN2 mutations, or for an autonomous pathogenic role for this specific point mutation in ATXN2 gene in driving the clinical phenotype toward ALS. We also found that stress granules in the fibroblasts from the patient entrapped higher amounts of defective ribosomal products compared to fibroblasts from three healthy subjects, suggesting that ATXN2 mutation-related toxicity may have implication in protein quality control.</AbstractText><CopyrightInformation>&#xa9; 2022. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghezzi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2566-3671</Identifier><AffiliationInfo><Affiliation>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. martinelli.ilaria88@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy. martinelli.ilaria88@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carra</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mediani</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucchi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonini</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cereda</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genomic and Post-Genomic Unit IRCCS - Mondino Foundation, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gellera</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Medical Genetics and Neurogenetics - Fondazione, IRCCS Istituto Neurologico 'Carlo Besta', Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pensato</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unit of Medical Genetics and Neurogenetics - Fondazione, IRCCS Istituto Neurologico 'Carlo Besta', Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2016-02364678</GrantID><Agency>Agenzia Italiana del Farmaco, Ministero della Salute</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593752">ATXN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATXN2</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Disease progression</Keyword><Keyword MajorTopicYN="N">Missense mutation</Keyword><Keyword MajorTopicYN="N">Stress granules</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>11</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35731316</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-06229-y</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-06229-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466(7310):1069&#x2013;1075. https://doi.org/10.1038/nature09320.PMID:20740007</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320.PMID:20740007</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId><ArticleId IdType="pmc">2965417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski LA, Hall AC, Mekhail K (2017) Ataxin-2: from RNA control to human health and disease. Genes (Basel) 8(6):157. https://doi.org/10.3390/genes8060157</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes8060157</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, Campanari ML, Julie Corbier C, Gaucherot A, Kolb-Cheynel I, Oulad-Abdelghani M et al (2016) Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J 35(12):1276&#x2013;97. https://doi.org/10.15252/embj.201593350</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201593350</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId><ArticleId IdType="pmc">4910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Lu Y, Xu XL, Gao FB (2013) The FTD/ALS-associated RNA-binding protein TDP-43 regulates the robustness of neuronal specification through microRNA-9a in Drosophila. Hum Mol Genet 22(2):218&#x2013;225. https://doi.org/10.1093/hmg/dds420.PMID:23042786</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds420.PMID:23042786</ArticleId><ArticleId IdType="pubmed">23042786</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP, Atkin JD (2013) Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet 22(4):717&#x2013;28. https://doi.org/10.1093/hmg/dds479</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds479</ArticleId><ArticleId IdType="pubmed">23172909</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML et al (2007) Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell 18(4):1385&#x2013;1396. https://doi.org/10.1091/mbc.e06-12-1120</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e06-12-1120</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId><ArticleId IdType="pmc">1838996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganassi M, Mateju D, Bigi I, Mediani L, Poser I, Lee HO et al (2016) A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Mol Cell 63(5):796&#x2013;810. https://doi.org/10.1016/j.molcel.2016.07.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.07.021</ArticleId><ArticleId IdType="pubmed">27570075</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P et al (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544(7650):367&#x2013;371. https://doi.org/10.1038/nature22038</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId><ArticleId IdType="pmc">5642042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Millecamps S, Stevanin G, Rivaud-P&#xe9;choux S, Moigneu C, Camuzat A et al (2014) French research network on FTD and FTD-ALS. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology 83(11):990&#x2013;5. https://doi.org/10.1212/WNL.0000000000000778</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000778</ArticleId><ArticleId IdType="pubmed">25098532</ArticleId><ArticleId IdType="pmc">4162303</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas I, Mart&#xed;nez C, Clarim&#xf3;n J, Lle&#xf3; A, Ill&#xe1;n-Gala I, Dols-Icardo O et al (2020) Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer&#x2019;s disease. Neurobiol Aging 87:139.e1-139.e7. https://doi.org/10.1016/j.neurobiolaging.2019.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.10.017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>